{"gene":"CPT1A","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":2020,"finding":"CPT1A catalyzes the rate-limiting step of mitochondrial fatty acid oxidation by converting long-chain acyl-CoA into acyl-carnitines, enabling their transport across the inner mitochondrial membrane; this activity is inhibited by malonyl-CoA.","method":"Review synthesizing enzymatic assays, genetic models, and metabolic studies","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 — biochemical mechanism replicated across decades and multiple labs","pmids":["31900483"],"is_preprint":false},{"year":2023,"finding":"Mitochondrial fragmentation reduces malonyl-CoA inhibition of CPT1A (increasing FAO), while mitochondrial elongation increases CPT1A sensitivity to malonyl-CoA inhibition, establishing mitochondrial morphology as a regulator of CPT1A activity and long-chain fatty acid utilization.","method":"Genetic manipulation of MFN2 and DRP1, respirometry, metabolic tracing (13C), CPT1 malonyl-CoA sensitivity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including reconstitution-level metabolic tracing and genetic perturbations in multiple cell types","pmids":["36917141"],"is_preprint":false},{"year":2021,"finding":"Butyrate is converted by ACSS2 to butyryl-CoA (BCoA), which antagonizes malonyl-CoA binding at Arg243 of CPT1A, thereby relieving malonyl-CoA inhibition, increasing CPT1A activity, promoting fatty acid oxidation, and facilitating iTreg differentiation.","method":"CPT1A mutagenesis (Arg243), ACSS2 inhibitor, metabolic assays, T cell differentiation assays, mouse colitis model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — site-directed mutagenesis identifies functional residue, corroborated by pharmacological and genetic inhibition with defined phenotype","pmids":["34035164"],"is_preprint":false},{"year":2018,"finding":"Baicalin directly activates hepatic CPT1A with isoform selectivity through allosteric binding; disruption of the predicted binding site abolished the beneficial anti-steatosis effects of baicalin.","method":"Quantitative chemoproteomic profiling, binding-site mutagenesis, in vivo metabolic assays in diet-induced obesity mouse model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — chemoproteomics identifies direct target, mutagenesis validates binding site, in vivo functional confirmation","pmids":["29891721"],"is_preprint":false},{"year":2023,"finding":"CPT1A recruits the ER-localized palmitoyltransferase ZDHHC4 to catalyze palmitoylation of MAVS at Cys79, which promotes MAVS stabilization and activation by inhibiting K48-linked and facilitating K63-linked ubiquitination, thereby sustaining type I interferon responses.","method":"Co-immunoprecipitation, palmitoylation assays, ubiquitination assays (K48/K63 linkage), genetic CPT1A manipulation, IFN-I reporter assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple biochemical assays (palmitoylation, ubiquitination, Co-IP) with specific residue (Cys79) and mechanistic pathway defined","pmids":["38016475"],"is_preprint":false},{"year":2022,"finding":"Mitochondrial STAT3 prevents CPT1A ubiquitination and degradation in macrophages through induction of the deubiquitinase USP50 (via NF-κB binding the USP50 promoter), thereby stabilizing CPT1A protein and promoting fatty acid oxidation during sepsis.","method":"Mass spectrometry, Co-immunoprecipitation (CPT1A-USP50), ChIP assay (NF-κB at USP50 promoter), USP50 knockdown, metabolic assays, knock-in mouse model","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP identifies CPT1A-USP50 interaction, ChIP validates NF-κB regulation, knockdown confirms functional consequence","pmids":["34976224"],"is_preprint":false},{"year":2021,"finding":"CPT1A directly interacts with Bcl-2 at its BH3 domain in mitochondria, anchoring Bcl-2 to prevent cytochrome C release and apoptosis; this interaction is dependent on CPT1A enzymatic activity and is present in lung macrophages from IPF patients.","method":"Co-immunoprecipitation, domain-mapping (BH3 domain), CPT1A activity inhibition, patient tissue analysis, bleomycin mouse model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with domain mapping, activity-dependence shown, validated in patient tissue and mouse model","pmids":["34413485"],"is_preprint":false},{"year":2023,"finding":"CPT1A promotes succinylation of mitochondrial fission factor (MFF) through its lysine succinyltransferase (LSTase) activity, which promotes mitochondria-associated membrane formation and SREBP1 activation, enhancing lipid desaturation and stemness in ovarian cancer stem cells.","method":"Succinylation assays, LSTase activity assays, CPT1A inhibition (Glyburide), Co-IP, in vitro and in vivo tumor models","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — novel enzymatic activity (LSTase) demonstrated biochemically with functional substrate identified, single lab","pmids":["39956875"],"is_preprint":false},{"year":2023,"finding":"SIRT1 deacetylates CPT1A at Lys675, suppressing its ubiquitin-dependent degradation, thereby stabilizing CPT1A protein and promoting fatty acid oxidation in hepatocytes.","method":"Co-immunoprecipitation, acetylation/deacetylation assays, site-directed mutagenesis (Lys675), SIRT1 overexpression/knockdown, CPT1A activity assays in HepG2 cells","journal":"Gastroenterology report","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus specific residue identification and functional assay, single lab","pmids":["37293270"],"is_preprint":false},{"year":2022,"finding":"CPT1A modulates the PHB2-PARL interaction by directly binding to PHB2; increased CPT1A activity (via L-carnitine or M593S mutation) enhances the PHB2-PARL interaction, promoting PINK1-Parkin-dependent mitophagy and improving mitochondrial function in cardiac endothelial cells.","method":"Co-immunoprecipitation, Western blotting, CPT1A activity assays with mutation (M593S), adenoviral overexpression, db/db mouse model","journal":"Acta physiologica (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP identifies CPT1A-PHB2 interaction, activity-dependence validated by mutation, in vivo and in vitro confirmation","pmids":["37042471"],"is_preprint":false},{"year":2023,"finding":"CPT1A covalently binds to Cys96 of its own protein when bound by the inhibitor DHP-B, which blocks FAO and disrupts the mitochondrial CPT1A-VDAC1 protein interaction, increasing mitochondrial permeability in colorectal cancer cells.","method":"Covalent binding assays, Co-immunoprecipitation (CPT1A-VDAC1), mitochondrial permeability assays, in vitro and in vivo tumor models","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP identifies CPT1A-VDAC1 interaction, specific binding residue (Cys96) identified, functional consequence demonstrated","pmids":["37977042"],"is_preprint":false},{"year":2023,"finding":"T cell-derived IFN-γ induces CPT1A expression and fatty acid oxidation in cancer cells through an AMPK-dependent mechanism, conferring resistance to cytotoxic T lymphocyte killing; CPT1A repression abrogates prosurvival signaling under immune cytolytic stress.","method":"CPT1A knockdown/overexpression, IFN-γ stimulation, AMPK inhibition, CTL cytotoxicity assays, Seahorse metabolic analysis, in vivo tumor models with CAR-T cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with defined cellular phenotype, upstream signal (IFN-γ/AMPK) identified, replicated in vivo","pmids":["37722058"],"is_preprint":false},{"year":2020,"finding":"CPT1A-dependent FAO promotes acetylation and nuclear translocation of β-catenin in colon cancer cells exposed to adipocytes; silencing CPT1A abolished β-catenin nuclear translocation and Wnt/β-catenin target gene expression.","method":"CPT1A knockdown, β-catenin acetylation assay, nuclear fractionation, Wnt target gene expression, xenograft tumor model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic link between CPT1A activity and β-catenin acetylation/localization demonstrated with KD and in vivo validation, single lab","pmids":["32913185"],"is_preprint":false},{"year":2024,"finding":"CPT1A restrains ubiquitination and degradation of c-Myc, while c-Myc transcriptionally activates CPT1A expression, forming a positive feedback loop that activates the NRF2/GPX4 antioxidant system and reduces ACSL4 expression to suppress ferroptosis in lung cancer stem cells.","method":"Lung epithelial-specific Cpt1a-knockout mouse model, metabolomics, transcriptomics, ubiquitination assays, ChIP assay (c-Myc on CPT1A promoter), ferroptosis assays","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1-2 — tissue-specific KO mouse, ChIP validates transcriptional regulation, ubiquitination assay defines mechanism, multiple orthogonal methods","pmids":["38453925"],"is_preprint":false},{"year":2024,"finding":"CPT1A loss in TP53-mutant hepatocellular carcinoma reduces acetyl-CoA production, which decreases histone acetylation and epigenetically represses BCAA catabolism, leading to BCAA accumulation and mTOR hyperactivation, creating sensitivity to mTOR inhibition.","method":"Genetic Cpt1a ablation, histone acetylation assays, metabolomics (acetyl-CoA, BCAA), mTOR signaling assays, xenograft and de novo liver tumor models, mTOR inhibitor treatment","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO with multiple metabolic readouts, epigenetic mechanism validated, pharmacological rescue confirms pathway","pmids":["38823763"],"is_preprint":false},{"year":2010,"finding":"PPARα and PGC-1α stimulate CPT1A transcription through distinct gene elements: PPARα acts through a binding site in the second intron, while PGC-1α acts through sequences in the first intron; PGC-1α knockdown does not abolish CPT1A induction by the PPARα ligand WY14643.","method":"PPARα binding site identification, luciferase reporter assays, PGC-1α shRNA knockdown, fasted rat in vivo model with luciferase vectors, WY14643 treatment","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 1 — reporter assay with mutagenesis and in vivo validation, epistasis by KD separates two regulatory elements","pmids":["20638986"],"is_preprint":false},{"year":2019,"finding":"Ethanol induces CPT1A promoter histone H3K9 deacetylation via HDAC1 recruitment mediated by SP1 (proximal region) and HNF4α (distal region), causing transcriptional repression; butyrate inhibits HDAC1 and enables p300-HAT binding to rescue CPT1A expression.","method":"Chromatin immunoprecipitation (ChIP) for HDAC1, SP1, HNF4α, p300 at CPT1A promoter; in vivo ethanol-fed mouse model; in vitro primary hepatocyte treatment","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP identifies specific transcription factors and histone marks at CPT1A promoter, validated in vivo and in vitro","pmids":["31654770"],"is_preprint":false},{"year":2018,"finding":"CPT1A interacts with Rab14, and this interaction facilitates trafficking of fatty acids from lipid droplets to mitochondria, decreasing radiation-induced lipid accumulation and maximizing ATP production to confer radiation resistance in nasopharyngeal carcinoma cells.","method":"LC-MS/MS interactome, Co-immunoprecipitation, immunofluorescence, proximity ligation assay, computational protein-protein interaction prediction, pulse-chase fatty acid trafficking assay (BODIPY C16/MitoTracker), Rab14 knockdown","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 — MS-identified interaction confirmed by Co-IP and proximity ligation, fatty acid trafficking functionally validated by pulse-chase","pmids":["29721083"],"is_preprint":false},{"year":2024,"finding":"CPT1A not only promotes FAO but also anchors Bcl-2 to the mitochondrial membrane in podocytes, preventing cytochrome C release and inhibiting the mitochondrial apoptotic pathway; a transcription factor FOXA1 was identified as a novel transcriptional regulator of CPT1A.","method":"CPT1A overexpression in streptozotocin-diabetic mice, Co-immunoprecipitation (CPT1A-Bcl2), cytochrome C release assays, FOXA1 ChIP/reporter assays, albuminuria and glomerulosclerosis readouts","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP identifies CPT1A-Bcl2 interaction with functional consequence, FOXA1 as transcription factor validated, single lab","pmids":["38506804"],"is_preprint":false},{"year":2024,"finding":"CPT1 inhibition (cardiac-specific Cpt1a/Cpt1b knockout or etomoxir) decreases PARP1 expression and reduces ADP-ribosylation of DUSP1, leading to decreased p38 MAPK phosphorylation and stimulation of cardiomyocyte proliferation and cardiac regeneration post-myocardial infarction.","method":"Cardiac-specific Cpt1a/Cpt1b knockout mice, etomoxir pharmacology, ADP-ribosylation assays of DUSP1, p38 MAPK phosphorylation assays, cardiomyocyte proliferation and cardiac function readouts","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO plus pharmacological confirmation, ADP-ribosylation of specific substrate identified, functional cardiac phenotype demonstrated","pmids":["40041918"],"is_preprint":false},{"year":2022,"finding":"CPT1A-mediated FAO promotes cell proliferation in nasopharyngeal carcinoma by generating acetyl equivalents and carbon precursors for nucleotide biosynthesis; 13C-palmitate tracing shows CPT1A knockdown reduces palmitate-derived carbons incorporated into pyrimidines.","method":"13C-palmitate isotopomer tracing, Seahorse XF analysis, CPT1A knockdown, nucleoside metabolite profiling, xenograft model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1-2 — 13C metabolic tracing directly links CPT1A activity to nucleotide biosynthesis, single lab","pmids":["35411000"],"is_preprint":false},{"year":2021,"finding":"CPT1A overexpression in renal tubular epithelial cells restores oxidative phosphorylation, increases palmitate oxidation and ATP levels, and reduces fibrotic marker expression; this gain-of-function protected against three models of renal fibrosis in conditional transgenic mice.","method":"Conditional CPT1A knock-in transgenic mouse, three fibrosis models (UUO, folic acid nephropathy, adenine), palmitate oxidation assays, ATP measurement, fibrosis scoring, AAV-mediated post-injury delivery","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — conditional transgenic model with multiple disease models, direct metabolic assays (palmitate oxidation, ATP), replicated with post-injury intervention","pmids":["33465052"],"is_preprint":false},{"year":2022,"finding":"Neutrophil chemotaxis and trafficking to sites of infection requires Cpt1a-dependent mitochondrial fatty acid oxidation for amplification of chemoattractant signals; pharmacologic Cpt1a inhibition impairs neutrophil trafficking and increases mortality in bacterial pneumonia.","method":"Pharmacological CPT1A inhibition in mouse pneumonia model, human phenome association study with CPT1A variant rs2229738_T, neutrophil chemotaxis assays, in vivo infection mortality studies","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological KO with defined cellular phenotype (chemotaxis), human genetics support, single lab","pmids":["36513703"],"is_preprint":false},{"year":2024,"finding":"RNF5 promotes K63-type ubiquitination of IGF2BP1, which enhances CPT1A mRNA stabilization through m6A modification, thereby increasing CPT1A protein levels and fatty acid oxidation in steatotic hepatocellular carcinoma.","method":"Protein interaction assays, ubiquitination assays (K63 linkage), m6A modification (MeRIP), CPT1A mRNA stability assays, lipidomics, transcriptomics","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic chain (RNF5→IGF2BP1 ubiquitination→m6A-CPT1A mRNA stability) supported by multiple biochemical assays, single lab","pmids":["39734009"],"is_preprint":false},{"year":2023,"finding":"IGF2BP1 directly recognizes and binds m6A sites on CPT1A mRNA and enhances its stability, with IGF2BP1 being stabilized by deubiquitinase USP10 that binds, deubiquitinates, and increases IGF2BP1 levels, ultimately mediating CPT1A-dependent breast cancer metastasis.","method":"MeRIP-seq, Co-IP, RNA pulldown, USP10 deubiquitination assay, CPT1A mRNA stability assays, in vitro and in vivo metastasis models","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 — MeRIP-seq identifies m6A sites, Co-IP and pulldown validate protein-RNA interactions, functional consequence in metastasis shown","pmids":["36632454"],"is_preprint":false},{"year":2023,"finding":"CPT1A interacts with the autophagy-related protein ATG16L1 and stimulates succinylation of ATG16L1, which drives autophagosome formation and autophagy, conferring chemoresistance in hypopharyngeal squamous cell carcinoma.","method":"Co-immunoprecipitation (CPT1A-ATG16L1), succinylation assays, autophagy flux assays, CPT1A inhibition, cisplatin sensitivity assays in vitro and in vivo","journal":"Cell insight","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP identifies interaction, succinylation of ATG16L1 as substrate, functional autophagy and drug resistance phenotype, single lab","pmids":["37961047"],"is_preprint":false},{"year":2002,"finding":"The human CPT1A gene spans 60 kb with 20 exons, has two alternate promoters, and numerous transcription factor-binding sites in the 5' upstream region; six novel loss-of-function mutations in CPT1A-deficient patients establish CPT1A as essential for mitochondrial long-chain fatty acid import and FAO in humans.","method":"Gene organization mapping using draft genome data, mutation identification by sequencing of exons/introns in CPT1A-deficient patients, CPT1 enzymatic activity in fibroblasts","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 — gene organization defined, loss-of-function mutations validated by enzyme activity, replicated in multiple patients","pmids":["12189492"],"is_preprint":false},{"year":2018,"finding":"Using T cell-specific Cpt1a knockout mice, long-chain fatty acid oxidation via the ACC2/Cpt1a axis is shown to be largely dispensable for effector, memory, and regulatory T cell formation; etomoxir effects on T cells are independent of Cpt1a expression.","method":"T cell-specific Cpt1a conditional knockout mice, T cell differentiation assays, memory and regulatory T cell functional assays, metabolic analysis","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO in specific cell type with defined phenotypic readouts, challenges previous pharmacological findings","pmids":["30043753"],"is_preprint":false},{"year":2024,"finding":"PACS2 positively regulates CPT1A expression in cardiomyocytes; silencing PACS2 downregulates CPT1A and upregulates DHODH, reversing high-glucose/palmitic-acid-induced ferroptosis, while CPT1A agonism in PACS2-silenced cells re-exacerbates ferroptosis and mitochondrial damage.","method":"PACS2 siRNA knockdown, CPT1A agonist, ferroptosis assays (iron, lipid peroxides, ROS), STZ/HFD mouse model, cardiac function and mitochondrial morphology analysis","journal":"Cardiovascular diabetology","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis experiment (PACS2 KD + CPT1A agonist rescue) places CPT1A downstream of PACS2, in vivo and in vitro validation, single lab","pmids":["39633391"],"is_preprint":false}],"current_model":"CPT1A is the rate-limiting outer mitochondrial membrane enzyme that catalyzes transfer of long-chain acyl groups from acyl-CoA to carnitine (forming acylcarnitines) for import into the mitochondrial matrix for β-oxidation; its activity is allosterically inhibited by malonyl-CoA (relievable by butyryl-CoA at Arg243), regulated by mitochondrial morphology, transcriptionally controlled by PPARα (second intron) and PGC-1α (first intron) through distinct gene elements, epigenetically repressed by HDAC1 recruitment via SP1/HNF4α, and post-translationally stabilized by USP50-mediated deubiquitination and SIRT1-mediated deacetylation at Lys675; beyond its canonical FAO role, CPT1A acts as a scaffolding/enzymatic hub that palmitoylates MAVS (via ZDHHC4 recruitment) to sustain antiviral innate immunity, succinylates MFF to regulate mitochondrial fission and SREBP1 activation, succinylates ATG16L1 to drive autophagy, interacts with Bcl-2 at the BH3 domain to prevent apoptosis, and binds PHB2 to maintain PINK1-Parkin mitophagy, collectively linking mitochondrial fatty acid metabolism to immune signaling, cell survival, and epigenetic regulation."},"narrative":{"teleology":[{"year":2002,"claim":"Defining the genomic architecture and establishing CPT1A as essential for human FAO: prior to this, CPT1A's full gene structure and disease-causing alleles were incompletely catalogued; mapping 20 exons across 60 kb and identifying six novel loss-of-function mutations in CPT1A-deficient patients confirmed CPT1A as indispensable for mitochondrial long-chain fatty acid import.","evidence":"Genomic mapping and sequencing of CPT1A exons/introns in deficiency patients with enzymatic validation in fibroblasts","pmids":["12189492"],"confidence":"High","gaps":["Genotype–phenotype correlations for individual mutations not established","Residual enzymatic activity thresholds for disease not defined"]},{"year":2010,"claim":"Resolving how CPT1A transcription is coordinately induced during fasting: it was unclear whether PPARα and PGC-1α acted through the same cis-element; reporter and knockdown experiments showed they use distinct intronic elements (second intron for PPARα, first intron for PGC-1α), establishing independent transcriptional axes.","evidence":"Luciferase reporters with mutagenesis, PGC-1α shRNA, and in vivo fasted rat model","pmids":["20638986"],"confidence":"High","gaps":["Identity of transcription factors mediating PGC-1α's effect through the first intron unknown","Chromatin context and enhancer looping not characterized"]},{"year":2018,"claim":"Two parallel advances refined CPT1A's regulatory and pharmacological landscape: (1) baicalin was identified as a direct allosteric CPT1A activator with isoform selectivity via chemoproteomics and binding-site mutagenesis; (2) T cell-specific Cpt1a knockout showed that long-chain FAO through CPT1A is largely dispensable for effector, memory, and regulatory T cell formation, challenging prior pharmacological conclusions based on etomoxir.","evidence":"Chemoproteomics with binding-site mutagenesis and in vivo metabolic readouts (baicalin); conditional T cell Cpt1a KO with differentiation and metabolic assays (T cell dispensability)","pmids":["29891721","30043753"],"confidence":"High","gaps":["Structural basis of baicalin's allosteric activation unresolved","Cell types where CPT1A-dependent FAO is truly essential versus dispensable remain context-dependent"]},{"year":2018,"claim":"Identifying a non-metabolic trafficking role: CPT1A was found to interact with Rab14, facilitating fatty acid transfer from lipid droplets to mitochondria, thereby linking CPT1A to intracellular lipid trafficking beyond its catalytic function at the outer mitochondrial membrane.","evidence":"LC-MS/MS interactome, Co-IP, proximity ligation assay, BODIPY-C16 pulse-chase in nasopharyngeal carcinoma cells","pmids":["29721083"],"confidence":"High","gaps":["Direct versus indirect nature of CPT1A–Rab14 interaction not fully resolved","Whether Rab14 interaction requires CPT1A enzymatic activity unknown"]},{"year":2019,"claim":"Uncovering epigenetic repression of CPT1A: ethanol was shown to recruit HDAC1 to the CPT1A promoter via SP1 (proximal) and HNF4α (distal), causing H3K9 deacetylation and transcriptional silencing, which butyrate reverses by inhibiting HDAC1 and enabling p300-HAT binding.","evidence":"ChIP for HDAC1, SP1, HNF4α, p300, and H3K9ac at CPT1A promoter in ethanol-fed mice and primary hepatocytes","pmids":["31654770"],"confidence":"High","gaps":["Whether other HDACs contribute to CPT1A silencing not tested","Genome-wide effects of ethanol on FAO gene promoters not assessed"]},{"year":2020,"claim":"Establishing CPT1A-dependent FAO as a driver of oncogenic Wnt signaling: CPT1A activity in adipocyte-exposed colon cancer cells was shown to promote acetylation and nuclear translocation of β-catenin, linking FAO-derived acetyl-CoA to epigenetic and transcriptional reprogramming.","evidence":"CPT1A knockdown, β-catenin acetylation assay, nuclear fractionation, xenograft model","pmids":["32913185"],"confidence":"Medium","gaps":["The acetyltransferase responsible for β-catenin acetylation downstream of CPT1A not identified","Whether this mechanism operates beyond adipocyte-exposed contexts is unclear"]},{"year":2021,"claim":"Two findings expanded CPT1A's role to anti-apoptotic signaling and tissue protection: CPT1A was shown to directly anchor Bcl-2 via its BH3 domain to prevent cytochrome C release in macrophages, and conditional CPT1A overexpression in renal tubular cells restored FAO and protected against kidney fibrosis in three independent models.","evidence":"Co-IP with BH3 domain mapping and activity-dependence in IPF lung tissue (apoptosis); conditional knock-in transgenic mouse with UUO, folic acid, and adenine fibrosis models (renal protection)","pmids":["34413485","33465052"],"confidence":"High","gaps":["Whether CPT1A–Bcl-2 interaction is regulated by metabolic state unknown","Structural basis of the BH3-domain interaction not resolved"]},{"year":2021,"claim":"Butyryl-CoA was identified as an endogenous antagonist of malonyl-CoA inhibition at CPT1A Arg243, linking gut-derived butyrate metabolism through ACSS2 to CPT1A activation and iTreg differentiation.","evidence":"CPT1A Arg243 mutagenesis, ACSS2 inhibitor, metabolic and T cell differentiation assays, mouse colitis model","pmids":["34035164"],"confidence":"High","gaps":["Whether other short-chain acyl-CoAs compete at Arg243 not tested","Structural mechanism of butyryl-CoA antagonism not determined"]},{"year":2022,"claim":"Post-translational stabilization of CPT1A was defined: mitochondrial STAT3 induces USP50 via NF-κB, and USP50 deubiquitinates CPT1A to prevent its proteasomal degradation, establishing a signaling axis that stabilizes CPT1A during sepsis-driven metabolic reprogramming in macrophages.","evidence":"Co-IP (CPT1A–USP50), ChIP (NF-κB at USP50 promoter), USP50 knockdown, knock-in mouse model","pmids":["34976224"],"confidence":"High","gaps":["Specific ubiquitin linkage type and E3 ligase targeting CPT1A for degradation not identified","Whether USP50 regulation of CPT1A operates outside macrophages unknown"]},{"year":2022,"claim":"CPT1A's role was extended to mitophagy regulation: CPT1A directly binds PHB2 and modulates the PHB2–PARL interaction to promote PINK1–Parkin-dependent mitophagy, with increased CPT1A activity (via M593S gain-of-function mutation) enhancing this process in cardiac endothelial cells.","evidence":"Co-IP, CPT1A M593S mutagenesis, adenoviral overexpression, db/db diabetic mouse model","pmids":["37042471"],"confidence":"Medium","gaps":["Whether CPT1A enzymatic activity or scaffolding is the critical determinant for PHB2 binding not separated","Confirmation in non-cardiac cell types lacking"]},{"year":2022,"claim":"CPT1A-dependent FAO was shown to provide carbon precursors for nucleotide biosynthesis: 13C-palmitate tracing demonstrated that CPT1A knockdown reduces palmitate-derived carbons incorporated into pyrimidines, directly linking FAO to proliferative capacity.","evidence":"13C-palmitate isotopomer tracing, nucleoside metabolite profiling, CPT1A knockdown in nasopharyngeal carcinoma","pmids":["35411000"],"confidence":"Medium","gaps":["Quantitative contribution of FAO versus other carbon sources to nucleotide pools not determined","Single cancer type studied"]},{"year":2023,"claim":"Mitochondrial morphology was established as a biophysical regulator of CPT1A: fragmentation reduces malonyl-CoA sensitivity (increasing FAO) while elongation increases it, revealing that the physical state of the outer mitochondrial membrane tunes CPT1A allosteric regulation.","evidence":"MFN2/DRP1 genetic manipulation, 13C metabolic tracing, CPT1 malonyl-CoA sensitivity assays in multiple cell types","pmids":["36917141"],"confidence":"High","gaps":["Biophysical mechanism by which membrane curvature alters malonyl-CoA binding not defined","Whether this applies to CPT1B and CPT1C isoforms unknown"]},{"year":2023,"claim":"A novel non-canonical enzymatic activity was attributed to CPT1A — lysine succinyltransferase (LSTase) activity: CPT1A succinylates MFF to promote mitochondria-associated membrane formation and SREBP1 activation, and succinylates ATG16L1 to drive autophagosome formation, revealing CPT1A as an acyltransferase with substrates beyond carnitine.","evidence":"Succinylation assays, LSTase activity assays, Co-IP (CPT1A–MFF, CPT1A–ATG16L1), autophagy flux assays, tumor models","pmids":["39956875","37961047"],"confidence":"Medium","gaps":["LSTase activity demonstrated by single lab; independent replication needed","Catalytic residues responsible for succinyltransferase activity not identified","Substrate scope of this activity unknown"]},{"year":2023,"claim":"CPT1A was shown to function as a scaffolding hub for innate antiviral immunity: CPT1A recruits the ER palmitoyltransferase ZDHHC4 to palmitoylate MAVS at Cys79, shifting ubiquitination from K48-linked (degradative) to K63-linked (activating) and sustaining type I interferon responses.","evidence":"Co-IP, palmitoylation and ubiquitination linkage assays, genetic CPT1A manipulation, IFN-I reporter assays","pmids":["38016475"],"confidence":"High","gaps":["Whether CPT1A enzymatic (acyltransfer) activity is required for ZDHHC4 recruitment not separated from scaffolding","How CPT1A on the outer mitochondrial membrane contacts ER-localized ZDHHC4 mechanistically unclear"]},{"year":2023,"claim":"SIRT1 was identified as a deacetylase stabilizing CPT1A: SIRT1 deacetylates Lys675, suppressing ubiquitin-dependent degradation, defining a second post-translational stabilization axis complementary to USP50-mediated deubiquitination.","evidence":"Co-IP, site-directed mutagenesis (K675), acetylation/deacetylation assays, SIRT1 overexpression/knockdown in HepG2","pmids":["37293270"],"confidence":"Medium","gaps":["The E3 ligase that ubiquitinates acetylated CPT1A not identified","Whether Lys675 acetylation and USP50-mediated deubiquitination converge on the same degradation pathway unknown"]},{"year":2023,"claim":"CPT1A mRNA stability was shown to be regulated by m6A-dependent mechanisms involving IGF2BP1, which recognizes m6A marks on CPT1A mRNA to enhance its stability; IGF2BP1 is itself stabilized by USP10 or activated by RNF5-mediated K63 ubiquitination.","evidence":"MeRIP-seq, RNA pulldown, Co-IP, deubiquitination/ubiquitination assays, mRNA stability assays in breast cancer and hepatocellular carcinoma","pmids":["36632454","39734009"],"confidence":"Medium","gaps":["Specific m6A sites on CPT1A mRNA functionally validated by mutagenesis not yet reported","Whether m6A regulation of CPT1A mRNA operates in non-cancer contexts unknown"]},{"year":2024,"claim":"CPT1A loss was linked to epigenetic and metabolic rewiring in hepatocellular carcinoma: Cpt1a ablation reduces acetyl-CoA, decreasing histone acetylation and repressing BCAA catabolism genes, causing BCAA accumulation and mTOR hyperactivation — creating a therapeutically exploitable vulnerability.","evidence":"Genetic Cpt1a ablation, histone acetylation and metabolomics assays, mTOR signaling, xenograft and de novo liver tumor models with mTOR inhibitor rescue","pmids":["38823763"],"confidence":"High","gaps":["Whether CPT1A-derived acetyl-CoA specifically acetylates histones at BCAA gene loci versus globally not resolved","Generalizability to non-TP53-mutant contexts untested"]},{"year":2024,"claim":"CPT1A was found to restrain c-Myc ubiquitination and degradation, forming a positive feedback loop (c-Myc transcriptionally activates CPT1A) that activates the NRF2/GPX4 antioxidant system and suppresses ferroptosis in lung cancer stem cells.","evidence":"Lung epithelial-specific Cpt1a KO mouse, ChIP (c-Myc on CPT1A promoter), ubiquitination assays, ferroptosis assays, metabolomics/transcriptomics","pmids":["38453925"],"confidence":"High","gaps":["Mechanism by which CPT1A inhibits c-Myc ubiquitination (direct interaction versus metabolic effect) not distinguished","Whether this loop operates in non-stem cancer cells unknown"]},{"year":2024,"claim":"CPT1 inhibition was shown to stimulate cardiomyocyte proliferation via reduced PARP1-mediated ADP-ribosylation of DUSP1, decreasing p38 MAPK phosphorylation, revealing a metabolic brake on cardiac regeneration.","evidence":"Cardiac-specific Cpt1a/Cpt1b double KO mice, etomoxir, ADP-ribosylation and p38 assays, cardiac function post-MI","pmids":["40041918"],"confidence":"Medium","gaps":["CPT1A versus CPT1B individual contributions not separated (double KO used)","How FAO inhibition decreases PARP1 expression mechanistically unclear"]},{"year":null,"claim":"Major open questions remain: the structural basis of CPT1A's allosteric regulation by malonyl-CoA and membrane curvature; whether the newly reported succinyltransferase (LSTase) activity is an intrinsic catalytic function or requires cofactors; the identity of the E3 ligase(s) targeting CPT1A for ubiquitin-dependent degradation; and how CPT1A scaffolding at the outer mitochondrial membrane coordinates with ER-resident partners (ZDHHC4) at membrane contact sites.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of full-length CPT1A with malonyl-CoA","LSTase activity awaits independent replication and catalytic-residue identification","E3 ligase(s) mediating CPT1A ubiquitination unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,3,7,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,6,9]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,9]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,6,7,9,10]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,3,20,21]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,13,18,28]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,11,22]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[9,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[15,16]}],"complexes":[],"partners":["BCL2","ZDHHC4","MAVS","PHB2","USP50","VDAC1","RAB14","ATG16L1"],"other_free_text":[]},"mechanistic_narrative":"CPT1A is the rate-limiting outer mitochondrial membrane enzyme that transfers long-chain acyl groups from coenzyme A to carnitine, generating acylcarnitines for import into the mitochondrial matrix and subsequent β-oxidation; this activity is allosterically inhibited by malonyl-CoA, with sensitivity modulated by mitochondrial morphology and antagonized by butyryl-CoA at Arg243 [PMID:31900483, PMID:36917141, PMID:34035164]. Transcription of CPT1A is driven through distinct intronic elements by PPARα and PGC-1α and is epigenetically repressed by HDAC1 recruited via SP1 and HNF4α, while post-translationally CPT1A protein is stabilized by USP50-mediated deubiquitination and SIRT1-mediated deacetylation at Lys675 [PMID:20638986, PMID:31654770, PMID:34976224, PMID:37293270]. Beyond its canonical metabolic role, CPT1A functions as a scaffolding and enzymatic hub: it recruits ZDHHC4 to palmitoylate MAVS for antiviral innate immune signaling, succinylates MFF and ATG16L1 to regulate mitochondrial fission and autophagy respectively, and anchors Bcl-2 at its BH3 domain to suppress the mitochondrial apoptotic pathway [PMID:38016475, PMID:39956875, PMID:37961047, PMID:34413485]. Loss-of-function mutations in CPT1A cause CPT1A deficiency, a Mendelian disorder of impaired hepatic long-chain fatty acid oxidation [PMID:12189492]."},"prefetch_data":{"uniprot":{"accession":"P50416","full_name":"Carnitine O-palmitoyltransferase 1, liver isoform","aliases":["Carnitine O-palmitoyltransferase I, liver isoform","CPT I","CPTI-L","Carnitine palmitoyltransferase 1A","Succinyltransferase CPT1A"],"length_aa":773,"mass_kda":88.4,"function":"Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion (PubMed:11350182, PubMed:14517221, PubMed:16651524, PubMed:9691089). Also possesses a lysine succinyltransferase activity that can regulate enzymatic activity of substrate proteins such as ENO1 and metabolism independent of its classical carnitine O-palmitoyltransferase activity (PubMed:29425493). Plays an important role in hepatic triglyceride metabolism (By similarity). Also plays a role in inducible regulatory T-cell (iTreg) differentiation once activated by butyryl-CoA that antagonizes malonyl-CoA-mediated CPT1A repression (By similarity). Sustains the IFN-I response by recruiting ZDHCC4 to palmitoylate MAVS at the mitochondria leading to MAVS stabilization and activation (PubMed:38016475). Promotes ROS-induced oxidative stress in liver injury via modulation of NFE2L2 and NLRP3-mediated signaling pathways (By similarity)","subcellular_location":"Mitochondrion outer membrane","url":"https://www.uniprot.org/uniprotkb/P50416/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CPT1A","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CPT1A","total_profiled":1310},"omim":[{"mim_id":"613486","title":"MICRO RNA 33B; MIR33B","url":"https://www.omim.org/entry/613486"},{"mim_id":"612795","title":"POLYUNSATURATED FATTY ACIDS PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; PUFAQTL1","url":"https://www.omim.org/entry/612795"},{"mim_id":"612156","title":"MICRO RNA 33A; MIR33A","url":"https://www.omim.org/entry/612156"},{"mim_id":"608846","title":"CARNITINE PALMITOYLTRANSFERASE IC; CPT1C","url":"https://www.omim.org/entry/608846"},{"mim_id":"605353","title":"GHRELIN; GHRL","url":"https://www.omim.org/entry/605353"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CPT1A"},"hgnc":{"alias_symbol":["CPT1-L","L-CPT1"],"prev_symbol":["CPT1"]},"alphafold":{"accession":"P50416","domains":[{"cath_id":"-","chopping":"1-48","consensus_level":"high","plddt":57.7008,"start":1,"end":48},{"cath_id":"-","chopping":"56-128_152-157","consensus_level":"high","plddt":88.1695,"start":56,"end":157},{"cath_id":"3.30.559.10","chopping":"181-238_545-763","consensus_level":"medium","plddt":95.8666,"start":181,"end":763},{"cath_id":"3.30.559.70","chopping":"263-542","consensus_level":"high","plddt":96.791,"start":263,"end":542}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50416","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50416-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50416-F1-predicted_aligned_error_v6.png","plddt_mean":92.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CPT1A","jax_strain_url":"https://www.jax.org/strain/search?query=CPT1A"},"sequence":{"accession":"P50416","fasta_url":"https://rest.uniprot.org/uniprotkb/P50416.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50416/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50416"}},"corpus_meta":[{"pmid":"31900483","id":"PMC_31900483","title":"CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31900483","citation_count":551,"is_preprint":false},{"pmid":"30043753","id":"PMC_30043753","title":"Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation.","date":"2018","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30043753","citation_count":327,"is_preprint":false},{"pmid":"29995871","id":"PMC_29995871","title":"CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29995871","citation_count":300,"is_preprint":false},{"pmid":"33465052","id":"PMC_33465052","title":"Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33465052","citation_count":277,"is_preprint":false},{"pmid":"29891721","id":"PMC_29891721","title":"Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29891721","citation_count":276,"is_preprint":false},{"pmid":"25122071","id":"PMC_25122071","title":"Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25122071","citation_count":257,"is_preprint":false},{"pmid":"29721083","id":"PMC_29721083","title":"Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/29721083","citation_count":224,"is_preprint":false},{"pmid":"26276667","id":"PMC_26276667","title":"Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26276667","citation_count":185,"is_preprint":false},{"pmid":"20638986","id":"PMC_20638986","title":"Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements.","date":"2010","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20638986","citation_count":172,"is_preprint":false},{"pmid":"38453925","id":"PMC_38453925","title":"Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38453925","citation_count":149,"is_preprint":false},{"pmid":"36917141","id":"PMC_36917141","title":"Mitochondrial morphology controls fatty acid utilization by changing CPT1 sensitivity to malonyl-CoA.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/36917141","citation_count":145,"is_preprint":false},{"pmid":"34035164","id":"PMC_34035164","title":"Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34035164","citation_count":141,"is_preprint":false},{"pmid":"34976224","id":"PMC_34976224","title":"Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34976224","citation_count":123,"is_preprint":false},{"pmid":"37033619","id":"PMC_37033619","title":"Mitochondrial CPT1A: Insights into structure, function, and basis for drug development.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37033619","citation_count":109,"is_preprint":false},{"pmid":"35411000","id":"PMC_35411000","title":"CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35411000","citation_count":99,"is_preprint":false},{"pmid":"34213835","id":"PMC_34213835","title":"iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34213835","citation_count":85,"is_preprint":false},{"pmid":"32666604","id":"PMC_32666604","title":"Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32666604","citation_count":82,"is_preprint":false},{"pmid":"22938691","id":"PMC_22938691","title":"Increased mitochondrial activity in BMP7-treated brown adipocytes, due to increased CPT1- and CD36-mediated fatty acid uptake.","date":"2012","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22938691","citation_count":81,"is_preprint":false},{"pmid":"3029130","id":"PMC_3029130","title":"Mutants of Saccharomyces cerevisiae defective in sn-1,2-diacylglycerol cholinephosphotransferase. Isolation, characterization, and cloning of the CPT1 gene.","date":"1987","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3029130","citation_count":80,"is_preprint":false},{"pmid":"35392915","id":"PMC_35392915","title":"The activation of PPARγ enhances Treg responses through up-regulating CD36/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TβRII/IL-2Rα.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/35392915","citation_count":79,"is_preprint":false},{"pmid":"38395901","id":"PMC_38395901","title":"ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38395901","citation_count":78,"is_preprint":false},{"pmid":"27916548","id":"PMC_27916548","title":"High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.","date":"2016","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27916548","citation_count":77,"is_preprint":false},{"pmid":"37722058","id":"PMC_37722058","title":"CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37722058","citation_count":75,"is_preprint":false},{"pmid":"34803493","id":"PMC_34803493","title":"Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34803493","citation_count":70,"is_preprint":false},{"pmid":"32913185","id":"PMC_32913185","title":"Upregulation of CPT1A is essential for the tumor-promoting effect of adipocytes in colon cancer.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32913185","citation_count":67,"is_preprint":false},{"pmid":"36632454","id":"PMC_36632454","title":"Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36632454","citation_count":66,"is_preprint":false},{"pmid":"26519879","id":"PMC_26519879","title":"High fructose consumption induces DNA methylation at PPARα and CPT1A promoter regions in the rat liver.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26519879","citation_count":63,"is_preprint":false},{"pmid":"24711635","id":"PMC_24711635","title":"Methylation at CPT1A locus is associated with lipoprotein subfraction profiles.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24711635","citation_count":63,"is_preprint":false},{"pmid":"32930325","id":"PMC_32930325","title":"Carbohydrate and fat intake associated with risk of metabolic diseases through epigenetics of CPT1A.","date":"2020","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/32930325","citation_count":59,"is_preprint":false},{"pmid":"36427397","id":"PMC_36427397","title":"CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36427397","citation_count":58,"is_preprint":false},{"pmid":"38016475","id":"PMC_38016475","title":"CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/38016475","citation_count":51,"is_preprint":false},{"pmid":"35028612","id":"PMC_35028612","title":"Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.","date":"2021","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35028612","citation_count":50,"is_preprint":false},{"pmid":"21733226","id":"PMC_21733226","title":"The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex.","date":"2011","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21733226","citation_count":49,"is_preprint":false},{"pmid":"34789275","id":"PMC_34789275","title":"A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis.","date":"2021","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/34789275","citation_count":48,"is_preprint":false},{"pmid":"30511343","id":"PMC_30511343","title":"CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertension.","date":"2018","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30511343","citation_count":48,"is_preprint":false},{"pmid":"30605728","id":"PMC_30605728","title":"Epigenetic regulation of carnitine palmitoyltransferase 1 (Cpt1a) by high fat diet.","date":"2018","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30605728","citation_count":47,"is_preprint":false},{"pmid":"37042471","id":"PMC_37042471","title":"L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways.","date":"2023","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37042471","citation_count":44,"is_preprint":false},{"pmid":"25501281","id":"PMC_25501281","title":"Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25501281","citation_count":44,"is_preprint":false},{"pmid":"34045663","id":"PMC_34045663","title":"Fatty acid β-oxidation promotes breast cancer stemness and metastasis via the miRNA-328-3p-CPT1A pathway.","date":"2021","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34045663","citation_count":43,"is_preprint":false},{"pmid":"31654770","id":"PMC_31654770","title":"Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury.","date":"2019","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31654770","citation_count":42,"is_preprint":false},{"pmid":"35728631","id":"PMC_35728631","title":"Inhibition of Cpt1a alleviates oxidative stress-induced chondrocyte senescence via regulating mitochondrial dysfunction and activating mitophagy.","date":"2022","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/35728631","citation_count":42,"is_preprint":false},{"pmid":"35408745","id":"PMC_35408745","title":"Rhein Improves Renal Fibrosis by Restoring Cpt1a-Mediated Fatty Acid Oxidation through SirT1/STAT3/twist1 Pathway.","date":"2022","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35408745","citation_count":41,"is_preprint":false},{"pmid":"34413485","id":"PMC_34413485","title":"Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34413485","citation_count":40,"is_preprint":false},{"pmid":"16362726","id":"PMC_16362726","title":"Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine.","date":"2005","source":"European journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16362726","citation_count":40,"is_preprint":false},{"pmid":"33218188","id":"PMC_33218188","title":"CPT1A Over-Expression Increases Reactive Oxygen Species in the Mitochondria and Promotes Antioxidant Defenses in Prostate Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33218188","citation_count":36,"is_preprint":false},{"pmid":"35130611","id":"PMC_35130611","title":"Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/35130611","citation_count":36,"is_preprint":false},{"pmid":"34052835","id":"PMC_34052835","title":"Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34052835","citation_count":36,"is_preprint":false},{"pmid":"12189492","id":"PMC_12189492","title":"Organization of the human liver carnitine palmitoyltransferase 1 gene ( CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12189492","citation_count":36,"is_preprint":false},{"pmid":"28611031","id":"PMC_28611031","title":"CPT1A Missense Mutation Associated With Fatty Acid Metabolism and Reduced Height in Greenlanders.","date":"2017","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28611031","citation_count":35,"is_preprint":false},{"pmid":"34331935","id":"PMC_34331935","title":"Differential contributions of choline phosphotransferases CPT1 and CEPT1 to the biosynthesis of choline phospholipids.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/34331935","citation_count":32,"is_preprint":false},{"pmid":"39090662","id":"PMC_39090662","title":"CPT1A-IL-10-mediated macrophage metabolic and phenotypic alterations ameliorate acute lung injury.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39090662","citation_count":30,"is_preprint":false},{"pmid":"39633391","id":"PMC_39633391","title":"PACS2/CPT1A/DHODH signaling promotes cardiomyocyte ferroptosis in diabetic cardiomyopathy.","date":"2024","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/39633391","citation_count":29,"is_preprint":false},{"pmid":"6328035","id":"PMC_6328035","title":"Vibrio cholerae bacteriophage CP-T1: characterization of bacteriophage DNA and restriction analysis.","date":"1984","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/6328035","citation_count":28,"is_preprint":false},{"pmid":"37977042","id":"PMC_37977042","title":"A novel CPT1A covalent inhibitor modulates fatty acid oxidation and CPT1A-VDAC1 axis with therapeutic potential for colorectal cancer.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37977042","citation_count":27,"is_preprint":false},{"pmid":"38823763","id":"PMC_38823763","title":"CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38823763","citation_count":27,"is_preprint":false},{"pmid":"17089095","id":"PMC_17089095","title":"Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase I (CPT1) gene interact with fat intake to modulate indices of obesity in French-Canadians.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17089095","citation_count":26,"is_preprint":false},{"pmid":"35567992","id":"PMC_35567992","title":"An integrated network pharmacology and cell metabolomics approach to reveal the role of rhein, a novel PPARα agonist, against renal fibrosis by activating the PPARα-CPT1A axis.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35567992","citation_count":26,"is_preprint":false},{"pmid":"35383152","id":"PMC_35383152","title":"The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35383152","citation_count":26,"is_preprint":false},{"pmid":"38914306","id":"PMC_38914306","title":"ASS1 enhances anoikis resistance via AMPK/CPT1A-mediated fatty acid metabolism in ovarian cancer.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38914306","citation_count":25,"is_preprint":false},{"pmid":"35911183","id":"PMC_35911183","title":"l-Carnitine therapy improves right heart dysfunction through Cpt1-dependent fatty acid oxidation.","date":"2022","source":"Pulmonary circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35911183","citation_count":25,"is_preprint":false},{"pmid":"22322067","id":"PMC_22322067","title":"Acetyl-L-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the L-carnitine content in the rat heart.","date":"2012","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/22322067","citation_count":25,"is_preprint":false},{"pmid":"36180554","id":"PMC_36180554","title":"The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36180554","citation_count":24,"is_preprint":false},{"pmid":"38195542","id":"PMC_38195542","title":"The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7.","date":"2024","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/38195542","citation_count":23,"is_preprint":false},{"pmid":"36513703","id":"PMC_36513703","title":"Neutrophil trafficking to the site of infection requires Cpt1a-dependent fatty acid β-oxidation.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36513703","citation_count":23,"is_preprint":false},{"pmid":"31810173","id":"PMC_31810173","title":"The PPARδ Agonist GW501516 Improves Lipolytic/Lipogenic Balance through CPT1 and PEPCK during the Development of Pre-Implantation Bovine Embryos.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31810173","citation_count":23,"is_preprint":false},{"pmid":"28315807","id":"PMC_28315807","title":"Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.","date":"2017","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/28315807","citation_count":23,"is_preprint":false},{"pmid":"23914904","id":"PMC_23914904","title":"Effects of cannabinoid receptor 1 (brain) on lipid accumulation by transcriptional control of CPT1A and CPT1B.","date":"2013","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23914904","citation_count":22,"is_preprint":false},{"pmid":"36702079","id":"PMC_36702079","title":"CPT1A modulates PI3K/Akt/mTOR pathway to promote preeclampsia.","date":"2023","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/36702079","citation_count":21,"is_preprint":false},{"pmid":"31527712","id":"PMC_31527712","title":"CPT1A plays a key role in the development and treatment of multiple sclerosis and experimental autoimmune encephalomyelitis.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31527712","citation_count":21,"is_preprint":false},{"pmid":"35453525","id":"PMC_35453525","title":"Vitamin D Counteracts Lipid Accumulation, Augments Free Fatty Acid-Induced ABCA1 and CPT-1A Expression While Reducing CD36 and C/EBPβ Protein Levels in Monocyte-Derived Macrophages.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35453525","citation_count":20,"is_preprint":false},{"pmid":"32916992","id":"PMC_32916992","title":"LRRK2 Regulates CPT1A to Promote β-Oxidation in HepG2 Cells.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32916992","citation_count":20,"is_preprint":false},{"pmid":"37293270","id":"PMC_37293270","title":"Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice.","date":"2023","source":"Gastroenterology report","url":"https://pubmed.ncbi.nlm.nih.gov/37293270","citation_count":20,"is_preprint":false},{"pmid":"20975105","id":"PMC_20975105","title":"Aerobic exercise's reversal of insulin resistance by activating AMPKα-ACC-CPT1 signaling in the skeletal muscle of C57BL/6 mice.","date":"2010","source":"International journal of sport nutrition and exercise metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20975105","citation_count":20,"is_preprint":false},{"pmid":"39956875","id":"PMC_39956875","title":"CPT1A-mediated MFF succinylation promotes stemness maintenance in ovarian cancer stem cells.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39956875","citation_count":19,"is_preprint":false},{"pmid":"36396930","id":"PMC_36396930","title":"Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres.","date":"2022","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36396930","citation_count":19,"is_preprint":false},{"pmid":"35511410","id":"PMC_35511410","title":"Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.","date":"2022","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/35511410","citation_count":19,"is_preprint":false},{"pmid":"34424821","id":"PMC_34424821","title":"Carnitine palmitoyltransferase 1 (CPT1) alleviates oxidative stress and apoptosis of hippocampal neuron in response to beta-Amyloid peptide fragment Aβ25-35.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34424821","citation_count":19,"is_preprint":false},{"pmid":"22701466","id":"PMC_22701466","title":"Variants in CPT1A, FADS1, and FADS2 are Associated with Higher Levels of Estimated Plasma and Erythrocyte Delta-5 Desaturases in Alaskan Eskimos.","date":"2012","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22701466","citation_count":19,"is_preprint":false},{"pmid":"32301324","id":"PMC_32301324","title":"Terpenoids from Resina Commiphora Regulating Lipid Metabolism via Activating PPARα and CPT1 Expression.","date":"2020","source":"Organic letters","url":"https://pubmed.ncbi.nlm.nih.gov/32301324","citation_count":18,"is_preprint":false},{"pmid":"37891690","id":"PMC_37891690","title":"Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer's disease at CPT1A locus.","date":"2023","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/37891690","citation_count":18,"is_preprint":false},{"pmid":"4065151","id":"PMC_4065151","title":"Bacteriophage CP-T1 of Vibrio cholerae. Identification of the cell surface receptor.","date":"1985","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/4065151","citation_count":18,"is_preprint":false},{"pmid":"38516886","id":"PMC_38516886","title":"Tubular CPT1A deletion minimally affects aging and chronic kidney injury.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/38516886","citation_count":17,"is_preprint":false},{"pmid":"37649600","id":"PMC_37649600","title":"Restoration of CPT1A-mediated fatty acid oxidation in mesothelial cells protects against peritoneal fibrosis.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/37649600","citation_count":17,"is_preprint":false},{"pmid":"27793752","id":"PMC_27793752","title":"Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27793752","citation_count":17,"is_preprint":false},{"pmid":"38506804","id":"PMC_38506804","title":"CPT1A Protects Podocytes From Lipotoxicity and Apoptosis In Vitro and Alleviates Diabetic Nephropathy In Vivo.","date":"2024","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/38506804","citation_count":16,"is_preprint":false},{"pmid":"37158903","id":"PMC_37158903","title":"Gastric cancer cell-originated small extracellular vesicle induces metabolic reprogramming of BM-MSCs through ERK-PPARγ-CPT1A signaling to potentiate lymphatic metastasis.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37158903","citation_count":16,"is_preprint":false},{"pmid":"40041918","id":"PMC_40041918","title":"Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation.","date":"2024","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/40041918","citation_count":16,"is_preprint":false},{"pmid":"37961047","id":"PMC_37961047","title":"CPT1A mediates chemoresistance in human hypopharyngeal squamous cell carcinoma via ATG16L1-dependent cellular autophagy.","date":"2023","source":"Cell insight","url":"https://pubmed.ncbi.nlm.nih.gov/37961047","citation_count":16,"is_preprint":false},{"pmid":"38003694","id":"PMC_38003694","title":"Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38003694","citation_count":16,"is_preprint":false},{"pmid":"34167568","id":"PMC_34167568","title":"Exogenous L-carnitine ameliorates burn-induced cellular and mitochondrial injury of hepatocytes by restoring CPT1 activity.","date":"2021","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34167568","citation_count":15,"is_preprint":false},{"pmid":"36402030","id":"PMC_36402030","title":"Atorvastatin ameliorates lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through inactivation of the p-STAT3/CPT1 pathway.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36402030","citation_count":15,"is_preprint":false},{"pmid":"32577118","id":"PMC_32577118","title":"Antiobesity and anti-inflammation effects of Hakka stir-fried tea of different storage years on high-fat diet-induced obese mice model via activating the AMPK/ACC/CPT1 pathway.","date":"2020","source":"Food & nutrition research","url":"https://pubmed.ncbi.nlm.nih.gov/32577118","citation_count":15,"is_preprint":false},{"pmid":"37207154","id":"PMC_37207154","title":"FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37207154","citation_count":15,"is_preprint":false},{"pmid":"36384580","id":"PMC_36384580","title":"WY-14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC.","date":"2022","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/36384580","citation_count":15,"is_preprint":false},{"pmid":"33378033","id":"PMC_33378033","title":"MiRNA-324-5p inhibits inflammatory response of diabetic vessels by targeting CPT1A.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33378033","citation_count":15,"is_preprint":false},{"pmid":"17445541","id":"PMC_17445541","title":"Lack of association of CPT1A polymorphisms or haplotypes on hepatic lipid content or insulin resistance in Japanese individuals with type 2 diabetes mellitus.","date":"2007","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/17445541","citation_count":15,"is_preprint":false},{"pmid":"38693136","id":"PMC_38693136","title":"TM7SF2-induced lipid reprogramming promotes cell proliferation and migration via CPT1A/Wnt/β-Catenin axis in cervical cancer cells.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38693136","citation_count":14,"is_preprint":false},{"pmid":"23430932","id":"PMC_23430932","title":"A Novel Mutation in CPT1A Resulting in Hepatic CPT Deficiency.","date":"2012","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/23430932","citation_count":14,"is_preprint":false},{"pmid":"26421611","id":"PMC_26421611","title":"The Origin and Diversity of Cpt1 Genes in Vertebrate Species.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26421611","citation_count":13,"is_preprint":false},{"pmid":"39734009","id":"PMC_39734009","title":"RNF5 exacerbates steatotic HCC by enhancing fatty acid oxidation via the improvement of CPT1A stability.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39734009","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54145,"output_tokens":7068,"usd":0.134227},"stage2":{"model":"claude-opus-4-6","input_tokens":10834,"output_tokens":5199,"usd":0.276218},"total_usd":0.410445,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"CPT1A catalyzes the rate-limiting step of mitochondrial fatty acid oxidation by converting long-chain acyl-CoA into acyl-carnitines, enabling their transport across the inner mitochondrial membrane; this activity is inhibited by malonyl-CoA.\",\n      \"method\": \"Review synthesizing enzymatic assays, genetic models, and metabolic studies\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical mechanism replicated across decades and multiple labs\",\n      \"pmids\": [\"31900483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Mitochondrial fragmentation reduces malonyl-CoA inhibition of CPT1A (increasing FAO), while mitochondrial elongation increases CPT1A sensitivity to malonyl-CoA inhibition, establishing mitochondrial morphology as a regulator of CPT1A activity and long-chain fatty acid utilization.\",\n      \"method\": \"Genetic manipulation of MFN2 and DRP1, respirometry, metabolic tracing (13C), CPT1 malonyl-CoA sensitivity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including reconstitution-level metabolic tracing and genetic perturbations in multiple cell types\",\n      \"pmids\": [\"36917141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Butyrate is converted by ACSS2 to butyryl-CoA (BCoA), which antagonizes malonyl-CoA binding at Arg243 of CPT1A, thereby relieving malonyl-CoA inhibition, increasing CPT1A activity, promoting fatty acid oxidation, and facilitating iTreg differentiation.\",\n      \"method\": \"CPT1A mutagenesis (Arg243), ACSS2 inhibitor, metabolic assays, T cell differentiation assays, mouse colitis model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-directed mutagenesis identifies functional residue, corroborated by pharmacological and genetic inhibition with defined phenotype\",\n      \"pmids\": [\"34035164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Baicalin directly activates hepatic CPT1A with isoform selectivity through allosteric binding; disruption of the predicted binding site abolished the beneficial anti-steatosis effects of baicalin.\",\n      \"method\": \"Quantitative chemoproteomic profiling, binding-site mutagenesis, in vivo metabolic assays in diet-induced obesity mouse model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemoproteomics identifies direct target, mutagenesis validates binding site, in vivo functional confirmation\",\n      \"pmids\": [\"29891721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CPT1A recruits the ER-localized palmitoyltransferase ZDHHC4 to catalyze palmitoylation of MAVS at Cys79, which promotes MAVS stabilization and activation by inhibiting K48-linked and facilitating K63-linked ubiquitination, thereby sustaining type I interferon responses.\",\n      \"method\": \"Co-immunoprecipitation, palmitoylation assays, ubiquitination assays (K48/K63 linkage), genetic CPT1A manipulation, IFN-I reporter assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple biochemical assays (palmitoylation, ubiquitination, Co-IP) with specific residue (Cys79) and mechanistic pathway defined\",\n      \"pmids\": [\"38016475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mitochondrial STAT3 prevents CPT1A ubiquitination and degradation in macrophages through induction of the deubiquitinase USP50 (via NF-κB binding the USP50 promoter), thereby stabilizing CPT1A protein and promoting fatty acid oxidation during sepsis.\",\n      \"method\": \"Mass spectrometry, Co-immunoprecipitation (CPT1A-USP50), ChIP assay (NF-κB at USP50 promoter), USP50 knockdown, metabolic assays, knock-in mouse model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP identifies CPT1A-USP50 interaction, ChIP validates NF-κB regulation, knockdown confirms functional consequence\",\n      \"pmids\": [\"34976224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CPT1A directly interacts with Bcl-2 at its BH3 domain in mitochondria, anchoring Bcl-2 to prevent cytochrome C release and apoptosis; this interaction is dependent on CPT1A enzymatic activity and is present in lung macrophages from IPF patients.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping (BH3 domain), CPT1A activity inhibition, patient tissue analysis, bleomycin mouse model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with domain mapping, activity-dependence shown, validated in patient tissue and mouse model\",\n      \"pmids\": [\"34413485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CPT1A promotes succinylation of mitochondrial fission factor (MFF) through its lysine succinyltransferase (LSTase) activity, which promotes mitochondria-associated membrane formation and SREBP1 activation, enhancing lipid desaturation and stemness in ovarian cancer stem cells.\",\n      \"method\": \"Succinylation assays, LSTase activity assays, CPT1A inhibition (Glyburide), Co-IP, in vitro and in vivo tumor models\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel enzymatic activity (LSTase) demonstrated biochemically with functional substrate identified, single lab\",\n      \"pmids\": [\"39956875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SIRT1 deacetylates CPT1A at Lys675, suppressing its ubiquitin-dependent degradation, thereby stabilizing CPT1A protein and promoting fatty acid oxidation in hepatocytes.\",\n      \"method\": \"Co-immunoprecipitation, acetylation/deacetylation assays, site-directed mutagenesis (Lys675), SIRT1 overexpression/knockdown, CPT1A activity assays in HepG2 cells\",\n      \"journal\": \"Gastroenterology report\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus specific residue identification and functional assay, single lab\",\n      \"pmids\": [\"37293270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CPT1A modulates the PHB2-PARL interaction by directly binding to PHB2; increased CPT1A activity (via L-carnitine or M593S mutation) enhances the PHB2-PARL interaction, promoting PINK1-Parkin-dependent mitophagy and improving mitochondrial function in cardiac endothelial cells.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, CPT1A activity assays with mutation (M593S), adenoviral overexpression, db/db mouse model\",\n      \"journal\": \"Acta physiologica (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifies CPT1A-PHB2 interaction, activity-dependence validated by mutation, in vivo and in vitro confirmation\",\n      \"pmids\": [\"37042471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CPT1A covalently binds to Cys96 of its own protein when bound by the inhibitor DHP-B, which blocks FAO and disrupts the mitochondrial CPT1A-VDAC1 protein interaction, increasing mitochondrial permeability in colorectal cancer cells.\",\n      \"method\": \"Covalent binding assays, Co-immunoprecipitation (CPT1A-VDAC1), mitochondrial permeability assays, in vitro and in vivo tumor models\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifies CPT1A-VDAC1 interaction, specific binding residue (Cys96) identified, functional consequence demonstrated\",\n      \"pmids\": [\"37977042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"T cell-derived IFN-γ induces CPT1A expression and fatty acid oxidation in cancer cells through an AMPK-dependent mechanism, conferring resistance to cytotoxic T lymphocyte killing; CPT1A repression abrogates prosurvival signaling under immune cytolytic stress.\",\n      \"method\": \"CPT1A knockdown/overexpression, IFN-γ stimulation, AMPK inhibition, CTL cytotoxicity assays, Seahorse metabolic analysis, in vivo tumor models with CAR-T cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined cellular phenotype, upstream signal (IFN-γ/AMPK) identified, replicated in vivo\",\n      \"pmids\": [\"37722058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CPT1A-dependent FAO promotes acetylation and nuclear translocation of β-catenin in colon cancer cells exposed to adipocytes; silencing CPT1A abolished β-catenin nuclear translocation and Wnt/β-catenin target gene expression.\",\n      \"method\": \"CPT1A knockdown, β-catenin acetylation assay, nuclear fractionation, Wnt target gene expression, xenograft tumor model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic link between CPT1A activity and β-catenin acetylation/localization demonstrated with KD and in vivo validation, single lab\",\n      \"pmids\": [\"32913185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CPT1A restrains ubiquitination and degradation of c-Myc, while c-Myc transcriptionally activates CPT1A expression, forming a positive feedback loop that activates the NRF2/GPX4 antioxidant system and reduces ACSL4 expression to suppress ferroptosis in lung cancer stem cells.\",\n      \"method\": \"Lung epithelial-specific Cpt1a-knockout mouse model, metabolomics, transcriptomics, ubiquitination assays, ChIP assay (c-Myc on CPT1A promoter), ferroptosis assays\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — tissue-specific KO mouse, ChIP validates transcriptional regulation, ubiquitination assay defines mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"38453925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CPT1A loss in TP53-mutant hepatocellular carcinoma reduces acetyl-CoA production, which decreases histone acetylation and epigenetically represses BCAA catabolism, leading to BCAA accumulation and mTOR hyperactivation, creating sensitivity to mTOR inhibition.\",\n      \"method\": \"Genetic Cpt1a ablation, histone acetylation assays, metabolomics (acetyl-CoA, BCAA), mTOR signaling assays, xenograft and de novo liver tumor models, mTOR inhibitor treatment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO with multiple metabolic readouts, epigenetic mechanism validated, pharmacological rescue confirms pathway\",\n      \"pmids\": [\"38823763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PPARα and PGC-1α stimulate CPT1A transcription through distinct gene elements: PPARα acts through a binding site in the second intron, while PGC-1α acts through sequences in the first intron; PGC-1α knockdown does not abolish CPT1A induction by the PPARα ligand WY14643.\",\n      \"method\": \"PPARα binding site identification, luciferase reporter assays, PGC-1α shRNA knockdown, fasted rat in vivo model with luciferase vectors, WY14643 treatment\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reporter assay with mutagenesis and in vivo validation, epistasis by KD separates two regulatory elements\",\n      \"pmids\": [\"20638986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ethanol induces CPT1A promoter histone H3K9 deacetylation via HDAC1 recruitment mediated by SP1 (proximal region) and HNF4α (distal region), causing transcriptional repression; butyrate inhibits HDAC1 and enables p300-HAT binding to rescue CPT1A expression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for HDAC1, SP1, HNF4α, p300 at CPT1A promoter; in vivo ethanol-fed mouse model; in vitro primary hepatocyte treatment\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP identifies specific transcription factors and histone marks at CPT1A promoter, validated in vivo and in vitro\",\n      \"pmids\": [\"31654770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CPT1A interacts with Rab14, and this interaction facilitates trafficking of fatty acids from lipid droplets to mitochondria, decreasing radiation-induced lipid accumulation and maximizing ATP production to confer radiation resistance in nasopharyngeal carcinoma cells.\",\n      \"method\": \"LC-MS/MS interactome, Co-immunoprecipitation, immunofluorescence, proximity ligation assay, computational protein-protein interaction prediction, pulse-chase fatty acid trafficking assay (BODIPY C16/MitoTracker), Rab14 knockdown\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified interaction confirmed by Co-IP and proximity ligation, fatty acid trafficking functionally validated by pulse-chase\",\n      \"pmids\": [\"29721083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CPT1A not only promotes FAO but also anchors Bcl-2 to the mitochondrial membrane in podocytes, preventing cytochrome C release and inhibiting the mitochondrial apoptotic pathway; a transcription factor FOXA1 was identified as a novel transcriptional regulator of CPT1A.\",\n      \"method\": \"CPT1A overexpression in streptozotocin-diabetic mice, Co-immunoprecipitation (CPT1A-Bcl2), cytochrome C release assays, FOXA1 ChIP/reporter assays, albuminuria and glomerulosclerosis readouts\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifies CPT1A-Bcl2 interaction with functional consequence, FOXA1 as transcription factor validated, single lab\",\n      \"pmids\": [\"38506804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CPT1 inhibition (cardiac-specific Cpt1a/Cpt1b knockout or etomoxir) decreases PARP1 expression and reduces ADP-ribosylation of DUSP1, leading to decreased p38 MAPK phosphorylation and stimulation of cardiomyocyte proliferation and cardiac regeneration post-myocardial infarction.\",\n      \"method\": \"Cardiac-specific Cpt1a/Cpt1b knockout mice, etomoxir pharmacology, ADP-ribosylation assays of DUSP1, p38 MAPK phosphorylation assays, cardiomyocyte proliferation and cardiac function readouts\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological confirmation, ADP-ribosylation of specific substrate identified, functional cardiac phenotype demonstrated\",\n      \"pmids\": [\"40041918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CPT1A-mediated FAO promotes cell proliferation in nasopharyngeal carcinoma by generating acetyl equivalents and carbon precursors for nucleotide biosynthesis; 13C-palmitate tracing shows CPT1A knockdown reduces palmitate-derived carbons incorporated into pyrimidines.\",\n      \"method\": \"13C-palmitate isotopomer tracing, Seahorse XF analysis, CPT1A knockdown, nucleoside metabolite profiling, xenograft model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — 13C metabolic tracing directly links CPT1A activity to nucleotide biosynthesis, single lab\",\n      \"pmids\": [\"35411000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CPT1A overexpression in renal tubular epithelial cells restores oxidative phosphorylation, increases palmitate oxidation and ATP levels, and reduces fibrotic marker expression; this gain-of-function protected against three models of renal fibrosis in conditional transgenic mice.\",\n      \"method\": \"Conditional CPT1A knock-in transgenic mouse, three fibrosis models (UUO, folic acid nephropathy, adenine), palmitate oxidation assays, ATP measurement, fibrosis scoring, AAV-mediated post-injury delivery\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — conditional transgenic model with multiple disease models, direct metabolic assays (palmitate oxidation, ATP), replicated with post-injury intervention\",\n      \"pmids\": [\"33465052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Neutrophil chemotaxis and trafficking to sites of infection requires Cpt1a-dependent mitochondrial fatty acid oxidation for amplification of chemoattractant signals; pharmacologic Cpt1a inhibition impairs neutrophil trafficking and increases mortality in bacterial pneumonia.\",\n      \"method\": \"Pharmacological CPT1A inhibition in mouse pneumonia model, human phenome association study with CPT1A variant rs2229738_T, neutrophil chemotaxis assays, in vivo infection mortality studies\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological KO with defined cellular phenotype (chemotaxis), human genetics support, single lab\",\n      \"pmids\": [\"36513703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RNF5 promotes K63-type ubiquitination of IGF2BP1, which enhances CPT1A mRNA stabilization through m6A modification, thereby increasing CPT1A protein levels and fatty acid oxidation in steatotic hepatocellular carcinoma.\",\n      \"method\": \"Protein interaction assays, ubiquitination assays (K63 linkage), m6A modification (MeRIP), CPT1A mRNA stability assays, lipidomics, transcriptomics\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic chain (RNF5→IGF2BP1 ubiquitination→m6A-CPT1A mRNA stability) supported by multiple biochemical assays, single lab\",\n      \"pmids\": [\"39734009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IGF2BP1 directly recognizes and binds m6A sites on CPT1A mRNA and enhances its stability, with IGF2BP1 being stabilized by deubiquitinase USP10 that binds, deubiquitinates, and increases IGF2BP1 levels, ultimately mediating CPT1A-dependent breast cancer metastasis.\",\n      \"method\": \"MeRIP-seq, Co-IP, RNA pulldown, USP10 deubiquitination assay, CPT1A mRNA stability assays, in vitro and in vivo metastasis models\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MeRIP-seq identifies m6A sites, Co-IP and pulldown validate protein-RNA interactions, functional consequence in metastasis shown\",\n      \"pmids\": [\"36632454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CPT1A interacts with the autophagy-related protein ATG16L1 and stimulates succinylation of ATG16L1, which drives autophagosome formation and autophagy, conferring chemoresistance in hypopharyngeal squamous cell carcinoma.\",\n      \"method\": \"Co-immunoprecipitation (CPT1A-ATG16L1), succinylation assays, autophagy flux assays, CPT1A inhibition, cisplatin sensitivity assays in vitro and in vivo\",\n      \"journal\": \"Cell insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifies interaction, succinylation of ATG16L1 as substrate, functional autophagy and drug resistance phenotype, single lab\",\n      \"pmids\": [\"37961047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The human CPT1A gene spans 60 kb with 20 exons, has two alternate promoters, and numerous transcription factor-binding sites in the 5' upstream region; six novel loss-of-function mutations in CPT1A-deficient patients establish CPT1A as essential for mitochondrial long-chain fatty acid import and FAO in humans.\",\n      \"method\": \"Gene organization mapping using draft genome data, mutation identification by sequencing of exons/introns in CPT1A-deficient patients, CPT1 enzymatic activity in fibroblasts\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gene organization defined, loss-of-function mutations validated by enzyme activity, replicated in multiple patients\",\n      \"pmids\": [\"12189492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Using T cell-specific Cpt1a knockout mice, long-chain fatty acid oxidation via the ACC2/Cpt1a axis is shown to be largely dispensable for effector, memory, and regulatory T cell formation; etomoxir effects on T cells are independent of Cpt1a expression.\",\n      \"method\": \"T cell-specific Cpt1a conditional knockout mice, T cell differentiation assays, memory and regulatory T cell functional assays, metabolic analysis\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO in specific cell type with defined phenotypic readouts, challenges previous pharmacological findings\",\n      \"pmids\": [\"30043753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PACS2 positively regulates CPT1A expression in cardiomyocytes; silencing PACS2 downregulates CPT1A and upregulates DHODH, reversing high-glucose/palmitic-acid-induced ferroptosis, while CPT1A agonism in PACS2-silenced cells re-exacerbates ferroptosis and mitochondrial damage.\",\n      \"method\": \"PACS2 siRNA knockdown, CPT1A agonist, ferroptosis assays (iron, lipid peroxides, ROS), STZ/HFD mouse model, cardiac function and mitochondrial morphology analysis\",\n      \"journal\": \"Cardiovascular diabetology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis experiment (PACS2 KD + CPT1A agonist rescue) places CPT1A downstream of PACS2, in vivo and in vitro validation, single lab\",\n      \"pmids\": [\"39633391\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CPT1A is the rate-limiting outer mitochondrial membrane enzyme that catalyzes transfer of long-chain acyl groups from acyl-CoA to carnitine (forming acylcarnitines) for import into the mitochondrial matrix for β-oxidation; its activity is allosterically inhibited by malonyl-CoA (relievable by butyryl-CoA at Arg243), regulated by mitochondrial morphology, transcriptionally controlled by PPARα (second intron) and PGC-1α (first intron) through distinct gene elements, epigenetically repressed by HDAC1 recruitment via SP1/HNF4α, and post-translationally stabilized by USP50-mediated deubiquitination and SIRT1-mediated deacetylation at Lys675; beyond its canonical FAO role, CPT1A acts as a scaffolding/enzymatic hub that palmitoylates MAVS (via ZDHHC4 recruitment) to sustain antiviral innate immunity, succinylates MFF to regulate mitochondrial fission and SREBP1 activation, succinylates ATG16L1 to drive autophagy, interacts with Bcl-2 at the BH3 domain to prevent apoptosis, and binds PHB2 to maintain PINK1-Parkin mitophagy, collectively linking mitochondrial fatty acid metabolism to immune signaling, cell survival, and epigenetic regulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CPT1A is the rate-limiting outer mitochondrial membrane enzyme that transfers long-chain acyl groups from coenzyme A to carnitine, generating acylcarnitines for import into the mitochondrial matrix and subsequent β-oxidation; this activity is allosterically inhibited by malonyl-CoA, with sensitivity modulated by mitochondrial morphology and antagonized by butyryl-CoA at Arg243 [PMID:31900483, PMID:36917141, PMID:34035164]. Transcription of CPT1A is driven through distinct intronic elements by PPARα and PGC-1α and is epigenetically repressed by HDAC1 recruited via SP1 and HNF4α, while post-translationally CPT1A protein is stabilized by USP50-mediated deubiquitination and SIRT1-mediated deacetylation at Lys675 [PMID:20638986, PMID:31654770, PMID:34976224, PMID:37293270]. Beyond its canonical metabolic role, CPT1A functions as a scaffolding and enzymatic hub: it recruits ZDHHC4 to palmitoylate MAVS for antiviral innate immune signaling, succinylates MFF and ATG16L1 to regulate mitochondrial fission and autophagy respectively, and anchors Bcl-2 at its BH3 domain to suppress the mitochondrial apoptotic pathway [PMID:38016475, PMID:39956875, PMID:37961047, PMID:34413485]. Loss-of-function mutations in CPT1A cause CPT1A deficiency, a Mendelian disorder of impaired hepatic long-chain fatty acid oxidation [PMID:12189492].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Defining the genomic architecture and establishing CPT1A as essential for human FAO: prior to this, CPT1A's full gene structure and disease-causing alleles were incompletely catalogued; mapping 20 exons across 60 kb and identifying six novel loss-of-function mutations in CPT1A-deficient patients confirmed CPT1A as indispensable for mitochondrial long-chain fatty acid import.\",\n      \"evidence\": \"Genomic mapping and sequencing of CPT1A exons/introns in deficiency patients with enzymatic validation in fibroblasts\",\n      \"pmids\": [\"12189492\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype correlations for individual mutations not established\", \"Residual enzymatic activity thresholds for disease not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Resolving how CPT1A transcription is coordinately induced during fasting: it was unclear whether PPARα and PGC-1α acted through the same cis-element; reporter and knockdown experiments showed they use distinct intronic elements (second intron for PPARα, first intron for PGC-1α), establishing independent transcriptional axes.\",\n      \"evidence\": \"Luciferase reporters with mutagenesis, PGC-1α shRNA, and in vivo fasted rat model\",\n      \"pmids\": [\"20638986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of transcription factors mediating PGC-1α's effect through the first intron unknown\", \"Chromatin context and enhancer looping not characterized\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Two parallel advances refined CPT1A's regulatory and pharmacological landscape: (1) baicalin was identified as a direct allosteric CPT1A activator with isoform selectivity via chemoproteomics and binding-site mutagenesis; (2) T cell-specific Cpt1a knockout showed that long-chain FAO through CPT1A is largely dispensable for effector, memory, and regulatory T cell formation, challenging prior pharmacological conclusions based on etomoxir.\",\n      \"evidence\": \"Chemoproteomics with binding-site mutagenesis and in vivo metabolic readouts (baicalin); conditional T cell Cpt1a KO with differentiation and metabolic assays (T cell dispensability)\",\n      \"pmids\": [\"29891721\", \"30043753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of baicalin's allosteric activation unresolved\", \"Cell types where CPT1A-dependent FAO is truly essential versus dispensable remain context-dependent\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying a non-metabolic trafficking role: CPT1A was found to interact with Rab14, facilitating fatty acid transfer from lipid droplets to mitochondria, thereby linking CPT1A to intracellular lipid trafficking beyond its catalytic function at the outer mitochondrial membrane.\",\n      \"evidence\": \"LC-MS/MS interactome, Co-IP, proximity ligation assay, BODIPY-C16 pulse-chase in nasopharyngeal carcinoma cells\",\n      \"pmids\": [\"29721083\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect nature of CPT1A–Rab14 interaction not fully resolved\", \"Whether Rab14 interaction requires CPT1A enzymatic activity unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovering epigenetic repression of CPT1A: ethanol was shown to recruit HDAC1 to the CPT1A promoter via SP1 (proximal) and HNF4α (distal), causing H3K9 deacetylation and transcriptional silencing, which butyrate reverses by inhibiting HDAC1 and enabling p300-HAT binding.\",\n      \"evidence\": \"ChIP for HDAC1, SP1, HNF4α, p300, and H3K9ac at CPT1A promoter in ethanol-fed mice and primary hepatocytes\",\n      \"pmids\": [\"31654770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other HDACs contribute to CPT1A silencing not tested\", \"Genome-wide effects of ethanol on FAO gene promoters not assessed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Establishing CPT1A-dependent FAO as a driver of oncogenic Wnt signaling: CPT1A activity in adipocyte-exposed colon cancer cells was shown to promote acetylation and nuclear translocation of β-catenin, linking FAO-derived acetyl-CoA to epigenetic and transcriptional reprogramming.\",\n      \"evidence\": \"CPT1A knockdown, β-catenin acetylation assay, nuclear fractionation, xenograft model\",\n      \"pmids\": [\"32913185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The acetyltransferase responsible for β-catenin acetylation downstream of CPT1A not identified\", \"Whether this mechanism operates beyond adipocyte-exposed contexts is unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Two findings expanded CPT1A's role to anti-apoptotic signaling and tissue protection: CPT1A was shown to directly anchor Bcl-2 via its BH3 domain to prevent cytochrome C release in macrophages, and conditional CPT1A overexpression in renal tubular cells restored FAO and protected against kidney fibrosis in three independent models.\",\n      \"evidence\": \"Co-IP with BH3 domain mapping and activity-dependence in IPF lung tissue (apoptosis); conditional knock-in transgenic mouse with UUO, folic acid, and adenine fibrosis models (renal protection)\",\n      \"pmids\": [\"34413485\", \"33465052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CPT1A–Bcl-2 interaction is regulated by metabolic state unknown\", \"Structural basis of the BH3-domain interaction not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Butyryl-CoA was identified as an endogenous antagonist of malonyl-CoA inhibition at CPT1A Arg243, linking gut-derived butyrate metabolism through ACSS2 to CPT1A activation and iTreg differentiation.\",\n      \"evidence\": \"CPT1A Arg243 mutagenesis, ACSS2 inhibitor, metabolic and T cell differentiation assays, mouse colitis model\",\n      \"pmids\": [\"34035164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other short-chain acyl-CoAs compete at Arg243 not tested\", \"Structural mechanism of butyryl-CoA antagonism not determined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-translational stabilization of CPT1A was defined: mitochondrial STAT3 induces USP50 via NF-κB, and USP50 deubiquitinates CPT1A to prevent its proteasomal degradation, establishing a signaling axis that stabilizes CPT1A during sepsis-driven metabolic reprogramming in macrophages.\",\n      \"evidence\": \"Co-IP (CPT1A–USP50), ChIP (NF-κB at USP50 promoter), USP50 knockdown, knock-in mouse model\",\n      \"pmids\": [\"34976224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ubiquitin linkage type and E3 ligase targeting CPT1A for degradation not identified\", \"Whether USP50 regulation of CPT1A operates outside macrophages unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CPT1A's role was extended to mitophagy regulation: CPT1A directly binds PHB2 and modulates the PHB2–PARL interaction to promote PINK1–Parkin-dependent mitophagy, with increased CPT1A activity (via M593S gain-of-function mutation) enhancing this process in cardiac endothelial cells.\",\n      \"evidence\": \"Co-IP, CPT1A M593S mutagenesis, adenoviral overexpression, db/db diabetic mouse model\",\n      \"pmids\": [\"37042471\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CPT1A enzymatic activity or scaffolding is the critical determinant for PHB2 binding not separated\", \"Confirmation in non-cardiac cell types lacking\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CPT1A-dependent FAO was shown to provide carbon precursors for nucleotide biosynthesis: 13C-palmitate tracing demonstrated that CPT1A knockdown reduces palmitate-derived carbons incorporated into pyrimidines, directly linking FAO to proliferative capacity.\",\n      \"evidence\": \"13C-palmitate isotopomer tracing, nucleoside metabolite profiling, CPT1A knockdown in nasopharyngeal carcinoma\",\n      \"pmids\": [\"35411000\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of FAO versus other carbon sources to nucleotide pools not determined\", \"Single cancer type studied\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mitochondrial morphology was established as a biophysical regulator of CPT1A: fragmentation reduces malonyl-CoA sensitivity (increasing FAO) while elongation increases it, revealing that the physical state of the outer mitochondrial membrane tunes CPT1A allosteric regulation.\",\n      \"evidence\": \"MFN2/DRP1 genetic manipulation, 13C metabolic tracing, CPT1 malonyl-CoA sensitivity assays in multiple cell types\",\n      \"pmids\": [\"36917141\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biophysical mechanism by which membrane curvature alters malonyl-CoA binding not defined\", \"Whether this applies to CPT1B and CPT1C isoforms unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A novel non-canonical enzymatic activity was attributed to CPT1A — lysine succinyltransferase (LSTase) activity: CPT1A succinylates MFF to promote mitochondria-associated membrane formation and SREBP1 activation, and succinylates ATG16L1 to drive autophagosome formation, revealing CPT1A as an acyltransferase with substrates beyond carnitine.\",\n      \"evidence\": \"Succinylation assays, LSTase activity assays, Co-IP (CPT1A–MFF, CPT1A–ATG16L1), autophagy flux assays, tumor models\",\n      \"pmids\": [\"39956875\", \"37961047\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LSTase activity demonstrated by single lab; independent replication needed\", \"Catalytic residues responsible for succinyltransferase activity not identified\", \"Substrate scope of this activity unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CPT1A was shown to function as a scaffolding hub for innate antiviral immunity: CPT1A recruits the ER palmitoyltransferase ZDHHC4 to palmitoylate MAVS at Cys79, shifting ubiquitination from K48-linked (degradative) to K63-linked (activating) and sustaining type I interferon responses.\",\n      \"evidence\": \"Co-IP, palmitoylation and ubiquitination linkage assays, genetic CPT1A manipulation, IFN-I reporter assays\",\n      \"pmids\": [\"38016475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CPT1A enzymatic (acyltransfer) activity is required for ZDHHC4 recruitment not separated from scaffolding\", \"How CPT1A on the outer mitochondrial membrane contacts ER-localized ZDHHC4 mechanistically unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"SIRT1 was identified as a deacetylase stabilizing CPT1A: SIRT1 deacetylates Lys675, suppressing ubiquitin-dependent degradation, defining a second post-translational stabilization axis complementary to USP50-mediated deubiquitination.\",\n      \"evidence\": \"Co-IP, site-directed mutagenesis (K675), acetylation/deacetylation assays, SIRT1 overexpression/knockdown in HepG2\",\n      \"pmids\": [\"37293270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The E3 ligase that ubiquitinates acetylated CPT1A not identified\", \"Whether Lys675 acetylation and USP50-mediated deubiquitination converge on the same degradation pathway unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CPT1A mRNA stability was shown to be regulated by m6A-dependent mechanisms involving IGF2BP1, which recognizes m6A marks on CPT1A mRNA to enhance its stability; IGF2BP1 is itself stabilized by USP10 or activated by RNF5-mediated K63 ubiquitination.\",\n      \"evidence\": \"MeRIP-seq, RNA pulldown, Co-IP, deubiquitination/ubiquitination assays, mRNA stability assays in breast cancer and hepatocellular carcinoma\",\n      \"pmids\": [\"36632454\", \"39734009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific m6A sites on CPT1A mRNA functionally validated by mutagenesis not yet reported\", \"Whether m6A regulation of CPT1A mRNA operates in non-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CPT1A loss was linked to epigenetic and metabolic rewiring in hepatocellular carcinoma: Cpt1a ablation reduces acetyl-CoA, decreasing histone acetylation and repressing BCAA catabolism genes, causing BCAA accumulation and mTOR hyperactivation — creating a therapeutically exploitable vulnerability.\",\n      \"evidence\": \"Genetic Cpt1a ablation, histone acetylation and metabolomics assays, mTOR signaling, xenograft and de novo liver tumor models with mTOR inhibitor rescue\",\n      \"pmids\": [\"38823763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CPT1A-derived acetyl-CoA specifically acetylates histones at BCAA gene loci versus globally not resolved\", \"Generalizability to non-TP53-mutant contexts untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CPT1A was found to restrain c-Myc ubiquitination and degradation, forming a positive feedback loop (c-Myc transcriptionally activates CPT1A) that activates the NRF2/GPX4 antioxidant system and suppresses ferroptosis in lung cancer stem cells.\",\n      \"evidence\": \"Lung epithelial-specific Cpt1a KO mouse, ChIP (c-Myc on CPT1A promoter), ubiquitination assays, ferroptosis assays, metabolomics/transcriptomics\",\n      \"pmids\": [\"38453925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CPT1A inhibits c-Myc ubiquitination (direct interaction versus metabolic effect) not distinguished\", \"Whether this loop operates in non-stem cancer cells unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CPT1 inhibition was shown to stimulate cardiomyocyte proliferation via reduced PARP1-mediated ADP-ribosylation of DUSP1, decreasing p38 MAPK phosphorylation, revealing a metabolic brake on cardiac regeneration.\",\n      \"evidence\": \"Cardiac-specific Cpt1a/Cpt1b double KO mice, etomoxir, ADP-ribosylation and p38 assays, cardiac function post-MI\",\n      \"pmids\": [\"40041918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CPT1A versus CPT1B individual contributions not separated (double KO used)\", \"How FAO inhibition decreases PARP1 expression mechanistically unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions remain: the structural basis of CPT1A's allosteric regulation by malonyl-CoA and membrane curvature; whether the newly reported succinyltransferase (LSTase) activity is an intrinsic catalytic function or requires cofactors; the identity of the E3 ligase(s) targeting CPT1A for ubiquitin-dependent degradation; and how CPT1A scaffolding at the outer mitochondrial membrane coordinates with ER-resident partners (ZDHHC4) at membrane contact sites.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of full-length CPT1A with malonyl-CoA\", \"LSTase activity awaits independent replication and catalytic-residue identification\", \"E3 ligase(s) mediating CPT1A ubiquitination unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 3, 7, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 6, 9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 6, 7, 9, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3, 20, 21]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 13, 18, 28]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 11, 22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [9, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [15, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"BCL2\",\n      \"ZDHHC4\",\n      \"MAVS\",\n      \"PHB2\",\n      \"USP50\",\n      \"VDAC1\",\n      \"RAB14\",\n      \"ATG16L1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}